Treating AD with BDNF can improve AD cognitive disorder.[19] Postmortem analyses of PD patients reveal decreased BDNF mRNA[20] and protein[21] expression in the substantia nigra (SN), implicating dysfunction of the BDNF/Trk-B signaling axis in the pathogenesis of PD. The gene discussed is NTRK2; the disease is Parkinson disease.